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Genomic alterations that occur early in tumorigenesis represent fundamental diver lesions and are perhaps of
highest priority as a means to intervene therapeutically. In this issue of Cancer Cell, Ozawa and colleagues
apply an algorithm to identify early events in glioblastoma and validate their findings in a rigorous manner.Human tumors, especially high grade ma-
lignant neoplasms, exhibit large numbers
of genomic changes compared to non-
neoplastic cells, but only a subset of those
abnormalities are likely to be crucial driver
events for tumor initiation and progres-
sion. Therefore, an important question
when faced with a wealth of genomic
data is to identify the critical abnormal-
ities. Early events maintained in the tumor
would be presumed to be critical for the
tumor and could potentially be identified
via serial sampling of tumors over time.
However, absent the ability to evaluate
multiple samples from the same individual
(for example matched primary-metastatic
or primary-recurrent pairs), efforts have
focused on cross-sectional data with a
single time point from multiple individuals
with the goal of inferring the likely
sequence of genetic events.
The concept of molecular subtypes of
glioblastoma (GBM) has a long history,
beginning with the distinction of primary
(also called de novo) and secondary
GBM (Scherer, 1940). Since then, our
understanding of GBM subtypes has
evolved following the advent of genome-
wide studies (Phillips et al., 2006; Verhaak
et al., 2010). Transcriptomal studies have
led to several classification systems, but a
consensus point to two principal and
recognized subtypes, the proneural and
mesenchymal classes. Further refinement
of the proneural class has distinguished
tumors with the glioma-CpG island meth-
ylator phenotype (GCIMP, often associ-
ated with IDH1 mutation; Noushmehr
et al., 2010) from IDH-wild-type/GCIMP-
negative tumors. While gene expression
studies have led to the concept of GBM
subclasses, the collective accumulation
of transcriptomal data, andmost recently,156 Cancer Cell 26, August 11, 2014 ª2014 Ethe study examining gene expression of
single cells (Patel et al., 2014), suggest
that the distinction between classes may
not be so rigid and can also lead to
mosaicism and/or the potential for
class switching, possibly under the influ-
ence of the tumor microenvironment
(Bhat et al., 2013). Plasticity among
GBM subtypes could then lead to a
concept that, while patient GBM samples
exhibit transcriptomal diversity, early
genetic events may be common to the
majority of GBM tumors. To examine this
possibility, in this issue of Cancer Cell,
Ozawa et al. (2014) apply a computational
method, Retracing Evolutionary Steps in
Cancer (RESIC), in an innovative manner
to infer a temporal sequence of genetic
alterations that occur during tumori-
genesis with reference to transcriptomal
subtypes.
In a prior publication, this group applied
RESIC to genomic data from colorectal
tumors to predict the temporal relation-
ships among alterations in the APC,
KRAS, and TP53 genes (Attolini et al.,
2010). Briefly, genetic events present in
the tumor population are provided as
input, and RESIC is designed to return
the likely sequence of events that
occurred, assuming a monoclonal origin.
Genetic alterations deemed to be pheno-
copies of each other (i.e., independent
alterations that similarly impact a specific
signaling pathway), are combined into
single alteration events. Following this,
genetic events that are found to be signif-
icantly correlated with each other are
identified. The RESIC algorithm then in-
fers the most likely sequence of events
among genetic alterations that occur
together, and a likely temporal sequence
leading up to the specific cancer subtypelsevier Inc.is constructed. Since this methodology is
applicable to large genomic data sets, the
authors applied RESIC to GBM samples
obtained from The Cancer Genome Atlas
data set. As the modern definition of
primary GBM has evolved into a group
of tumors defined as those without IDH
mutation, the authors very intelligently
chose to focus only on GCIMP-negative
tumors in their analysis. In a previous
publication (Cheng et al., 2012), only the
focal genetic/genomic changes and later
events to highlight distinctions between
transcriptomal subtypes were focused
upon. Ozawa et al. (2014) extend these
findings substantially with a more in-
depth analysis, including whole-arm and
whole-chromosomal events within the
RESIC algorithm to estimate the temporal
sequence of events that lead to primary
GBM. To validate their approach, predic-
tions were experimentally tested both in
culture and, drawing upon the team’s
strengths, in mouse modeling.
Ozawa et al. (2014) found that whole-
chromosome gains of seven and losses
of ten are seen in the vast majority
(80%–90%) of CIMP-negative GBMs,
raising the question: which are the driver
genes subsumed by these large genomic
changes?With respect to chromosome 7,
the authors first correlate the presence
of chromosome 7 gain with the expres-
sion of genes located on this chromo-
some to narrow the list of candidate
genes to those most tightly regulated
to gene dosage. Interestingly, EGFR,
perhaps the most studied chromosome
7 gene in GBM, was not among those
highly correlated to low-level chromo-
some 7 gain. Subsequently, they identi-
fied those chromosome 7 genes and their
relevant downstream pathways, which
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PDGFA was found to be the highest
ranked gene using these criteria, linking
it as a potential early driver event. A similar
approach toward the identification of
underexpressed genes led to the identifi-
cation of PTEN as a potential chromo-
some 10 driver tumor-suppressive gene.
With PDGFA and PTEN identified as
driver chromosome 7 and 10 GBM genes,
respectively, the authors directly tested
these using their RCAS glioma modeling
system. Using Nestin/tv-a or GFAP/tv-a
mice, they found that overexpression of
PDGFA alone was sufficient to initiate
gliomas in vivo. While Pten loss alone
did not initiate glioma, the addition of
Pten knockdown to PDGFA overexpres-
sion increased malignancy grade and
decreased the survival of the mice.
Hints toward the relationships between
genomic events to transcriptomal sub-
class were found by a comparison of
PDGFA- versus PDGFB-induced tumors,
where PDGFA tumors were proneural
while PDGFB tumors, accentuated by
atypical vasculature and stroma, ex-
hibited a mesenchymal phenotype.
Knockdown of Tp53 in PDGFA-driven
glioma led to high-grade histology and
shortened mouse survival, while tumors
retained their proneural character. To
link genetic events and transcripto-
mal subtype, the authors noted prior
work correlating loss of NF1 with the
mesenchymal phenotype (Verhaak et al.,
2010) and showed that Nf1 knockdown
in PDGFRA-amplified proneural glioma
lead to mesenchymal characteristics.
This finding adds to prior evidence to sub-stantiate the hypothesis that the mesen-
chymal phenotype can arise in the setting
of a proneural tumor (Phillips et al., 2006;
Bhat et al., 2013). Interestingly, the
mechanisms by which this occurred
could be related to reports on master
transcriptional regulators of the mesen-
chymal phenotype, including C/EBPb
and RUNX1 (Carro et al., 2010). In vivo,
loss of Nf1 correlated with acquisition of
mesenchymal markers (CD44, pSTAT3,
and C/EBPb) in the mouse glioma model.
Overall, using mathematical modeling
of human GBM to predict chromosome
7 gain and 10 loss as early genetic events,
the authors identified the driver genes un-
derlying these events and validated their
role in gliomagenesis in animal models.
Based on the finding that the early events
lead to proneural GBM, they conclude,
consistent with the finding that NF1 loss
is a later event in human GBMs, that
mesenchymal GBMs evolve from a pro-
neural-like precursor. While the dynamic
nature of gene expression has perhaps
contributed to variability in the specifics
of GBM transcriptomal classes (Phillips
et al., 2006; Verhaak et al., 2010), the
fact that the frequency of chromosome 7
gain/10 loss is a general feature of IDH-
wild-type/non-CIMP GBM provides a
firm basis for focusing on these changes
as fundamental to this tumor entity. While
EGFR exhibits high-level amplification in a
subset of GBM, evidence here suggests
this may be a later event. While RESIC is
not a discovery tool per se, and is of
necessity limited to available genomic
data as the input, this work, by combining
mathematics with experimental valida-Cancer Cell 26tion, highlights its utility to identify key
driver events in GBM.REFERENCES
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